Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CELGENE

(CELG)
  Report
SummaryChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

BX Swiss AG uses Blockchain technology to protect approved securities prospectuses against falsification

06/18/2020 | 03:05am EDT

BX Swiss AG uses Blockchain technology to protect approved securities prospectuses against falsification

As part of its role as a prospectus review office under the Financial Services Act, BX Swiss reviews and deposits securities prospectuses. In order to ensure that prospectuses always correspond to the approved version, BX Swiss has integrated the certification solution from Certifaction. After verification, the documents are digitally signed and stored in an unalterable form via the Ethereum Blockchain.

"COVID-19 has exponentially accelerated the digital transformation," says Manuel Gall, Co-Founder at Certifaction. "This has tremendously increased the need to protect digital documents such as prospectuses, diplomas, medical prescriptions or credit ratings against forgery or unauthorized manipulation."

"The security procedure that we were able to implement with Certifaction allows us to register prospectuses on the block chain forgery-proof within a few minutes and to provide investors with a simple tool for checking the authenticity of a document," adds Matthias Müller, Managing Director at BX Swiss AG.

Every investor can check the authenticity of a prospectus with a simple drag & drop via the BX Swiss website:

https://www.regservices.ch/en/prospectus-verification/

Contact for queries:

Matthias Müller

Managing Director

Tel.: +41 31 329 40 44

matthias.mueller@bxswiss.com




Provider
Channel
Contact
EQS Group Ltd., Switzerland
switzerland.eqs.com


newsbox.ch
www.newsbox.ch


Provider/Channel related enquiries
cs.switzerland@eqs.com
+41 41 763 00 50
All news about CELGENE
09/07Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential..
CI
08/04CELGENE : Sun Pharma And Celegene Settle Patent Dispute Over Lenalidomide (Revlimid®)
AQ
07/09BESRA GOLD INC : Announces Lodgment of Replacement Prospectus & Adjournment of Note Holder..
NE
06/21Celgene Corporation Will Grant Sun Pharmaceutical Industries Limited A License to Celge..
CI
04/14CELGENE : Rocket docket pharma patent litigation taking off in Australia and other emergin..
AQ
04/07DGAP-WPÜG : Tender Offer / Target company: ; Bidder: qqqqq
EQ
03/25Cadila Healthcare Limited - Zydus Announces Settlement of Patent Litigation for Generic..
AQ
03/25Leonteq becomes new issuer on BX Swiss – “deriBX”
TE
02/23BRISTOL MYERS SQUIBB CO : Other Events (form 8-K)
AQ
02/23Bristol Myers Squibb and Celgene Issue Notices of Redemption and Partial Redemption of ..
AQ
More news
Analyst Recommendations on CELGENE
More recommendations
Financials (USD)
Sales 2018 15 281 M - -
Net income 2018 4 046 M - -
Net Debt 2018 14 221 M - -
P/E ratio 2018 11,6x
Yield 2018 -
Capitalization 77 036 M 77 036 M -
EV / Sales 2017 6,61x
EV / Sales 2018 3,86x
Nbr of Employees 8 852
Free-Float -
Chart CELGENE
Duration : Period :
Celgene Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Matt M. Roden President & Director
David V. Elkins CFO, Principal Accounting Officer & Executive VP
P. Joseph Campisi Director & Vice President
Katherine Reynolds Kelly Secretary & Director
Jeffrey Galik Treasurer